|
Key
Features: |
|
| Title and year of the Document | A Hungarian proposal for methodology standards, 2002 |
| Affiliation of authors | Ministry of Health and academia |
| Main policy objective | To support the decision-making process with sound C/E data and good quality economic study. |
| Standard reporting format included | Yes |
| Disclosure | Yes |
| Target audience of funding/ author’s interests | Manufacturers, sponsors, health providers, policy makers and purchasers of healthcare services |
| Perspective | The audience to whom the analysis is addressed. If more than one perspective, be reported clearly and separately. |
| Indication | Licensed one(s) |
| Target population | Yes |
| Subgroup analysis | Yes |
| Choice of comparator | Current accepted standard therapy that could be replaced. The selection should be justified. |
| Time horizon | Long enough to cover all significant clinical and cost consequences that are directly related to the intervention. |
| Assumptions required | Yes |
| Preferred analytical technique | CMA, CEA, CUA |
| Costs to be included | Depends on the perspective of the study |
| Source of costs | Be clearly stated. If it is from the perspective of the National Health Insurance Fund (OEP), the sources should be finance fees defined in OEP contracts and costs data of the Information Center for Healthcare. |
| Modeling | Yes |
| Systematic review of evidences | Yes |
| Preference for effectiveness over efficacy | Yes, modeling and/or sensitivity analysis should be used to extrapolate efficacy data |
| Preferred outcome measure | Final outcome and changes in QoL, QALY |
| Preferred method to derive utility | Validated Hungarian version of EQ-5D |
| Equity issues stated | Yes |
| Discounting costs | Base: 5%; SA: 3-6% |
| Discounting outcomes | Base: 5%; SA: 0-6% |
| Sensitivity analysis-parameters and range | On uncertain parameters. |
| Sensitivity analysis-methods | One-way, two–way. |
| Presenting results | For clarity, reproducibility, and future use of data, results of total costs and total gains should be clearly stated. |
| Incremental analysis | Yes |
| Total C/E | Yes |
| Portability of results (Generalizability) | Yes. Guideline 5.6, 8.3 |
| Financial impact analysis | Yes, guideline 5.7, 9.1. Impact over the 3- to 5-year period should be discussed. |
| Mandatory or recommended or voluntary | Recommended |
